Microplastics and Misinformation: What Science Really Says
November 12, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Coreg, coreg CR
Synonyms :
Class :
Antihypertensive, Beta-blockers
Brand Name :
Coreg, coreg CR
Synonyms :
Class :
Antihypertensive, Beta-blockers
Dosage Forms & StrengthsÂ
Capsule, extended release-10mg,20mg,40mg,80mgÂ
Tablet-3.125mg,6.25mg,12.5mg,25mgÂ
Congestive Heart Failure (CHF)
Immediate release:
3.125
mg
orally
every 12 hrs
14
days
then increase every two weeks tolerated to 6.25mg,12.5mg, or 25 mg orally twice a day
Maximum recommended dose:
Mild to moderate heart failure:
<85 kg,25mg orally every 12 hours
>85kg,50mg orally twice daily
Severe heart failure:
25mg orally twice a day
Extended-release
10mg/day orally for 1-2 weeks, then increase 20mg/day,40mg/day, and 80mg/day orally
25 - 50
mg
Tablet
Orally 
twice a day
Left Ventricular Dysfunction Following Myocardial Infarction
Immediate release:
3.125 - 6.25
mg
Tablet
Orally 
every 12 hrs
3 - 10
days
then increase to 12.5mg orally every 12 hours and then to 25mg orally every 12 hours
Extended-release
10mg/day orally for 3-10days, then increase to 80mg/day orally
Immediate release:
6.25
mg
Tablet
orally
twice a day
14
days
then increase to 12.5mg orally twice a day and then to 25 mg orally twice a day
Extended-release
20mg/day orally for 1-2 weeks, then increase to 40mg/day orally. Do not exceed 80mg/day orally
Dose Adjustments
Renal impairment: No dosage adjustment is necessary
Hepatic impairment: Not preferred in severe liver impairment
carvedilol: it may increase the risk of methemoglobinemia associated agents
carvedilol: it may increase the risk of methemoglobinemia associated agents
carvedilol: it may increase the risk of methemoglobinemia associated agents
carvedilol: it may increase the risk of methemoglobinemia associated agents
carvedilol: it may increase the risk of methemoglobinemia associated agents
may increase the serum concentration of talazoparib 
may decrease the therapeutic effect when combined with tasimelteon
may have an increased AV-blocking effect when combined with beta-blockers
may have an increased AV-blocking effect when combined with beta-blockers
may have an increased AV-blocking effect when combined with beta-blockers
may have an increased AV-blocking effect when combined with beta-blockers
may have an increased AV-blocking effect when combined with beta-blockers
may have an increased AV-blocking effect when combined with beta-blockers
may decrease the antihypertensive effect when both drugs are combined
may decrease the antihypertensive effect when both drugs are combined
it enhances by affecting the hepatic enzyme CYP2C9 metabolism
it enhances by affecting the P-Glycoprotein (MDR1) efflux transporter
it enhances by affecting the hepatic enzyme CYP2C9 metabolism
May enhances the effects of the other by pharmacodynamic synergism
it enhances by affecting the P-Glycoprotein (MDR1) efflux transporter
It enhances the anti-hypertensive channel blocking when combined
it enhances by affecting the P-Glycoprotein (MDR1) efflux transporter
may increase the levels of each other by decreasing the metabolism
it enhances by affecting the P-Glycoprotein (MDR1) efflux transporter
May diminish the effects of carvedilol by pharmacodynamic antagonism
may decrease the bronchodilatory effect
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with Beta2-Agonists
may decrease the bronchodilatory effect when combined with Beta2-Agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may decrease the bronchodilatory effect
may have an increased bradycardic effect when combined with beta-blockers
may decrease the bronchodilatory effect of beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
beta-Blockers may enhance the hypoglycemic effect of sulfonylureas
beta-Blockers may enhance the hypoglycemic effect of sulfonylureas
beta-Blockers may enhance the hypoglycemic effect of sulfonylureas
beta-Blockers may enhance the hypoglycemic effect of sulfonylureas
beta-Blockers may enhance the hypoglycemic effect of sulfonylureas
it may enhance the serum potassium levels
It enhances the anti-hypertensive channel blocking when combined
May enhances the effects of the other by pharmacodynamic synergism
it enhances by affecting the hepatic enzyme CYP2C9 metabolism
it decreases by affecting the hepatic enzyme CYP2C9 metabolism
it enhances by affecting the hepatic enzyme CYP2C9 metabolism
it enhances the serum potassium levels
it decreases by affecting the hepatic enzyme CYP2C9 metabolism
May enhances the effects of the other by pharmacodynamic synergism
it may decrease the serum potassium levels
may increase the levels of each other by decreasing the metabolism
it enhances by affecting the hepatic enzyme CYP2C9 metabolism
it enhances the serum potassium levels
it may decrease the serum potassium levels
it enhances by affecting the P-Glycoprotein (MDR1) efflux transporter
it enhances by affecting the P-Glycoprotein (MDR1) efflux transporter
it may decrease the serum potassium levels
May enhances the effects of the other by pharmacodynamic synergism
it enhances by affecting the hepatic enzyme CYP2C9 metabolism
It enhances the anti-hypertensive channel blocking when combined
it enhances the serum potassium levels
May enhances the effects of the other by pharmacodynamic synergism
it enhances the serum potassium levels
May diminish the effects of propranolol by pharmacodynamic antagonism
it enhances by affecting the hepatic enzyme CYP2C9 metabolism
it enhances by affecting the hepatic enzyme CYP2C9 metabolism
It enhances the anti-hypertensive channel blocking when combined
it enhances the serum potassium levels
it decreases by affecting the hepatic enzyme CYP2C9 metabolism
May enhances the effects of the other by pharmacodynamic synergism
it enhances by affecting the P-Glycoprotein (MDR1) efflux transporter
May enhances the effects of the other by pharmacodynamic synergism
it enhances the serum potassium levels
it enhances by affecting the hepatic enzyme CYP2D6 metabolism
it enhances by affecting the hepatic enzyme CYP2D6 metabolism
may enhance the hypoglycemic effect of antidiabetic agents
may enhance the hypoglycemic effect of antidiabetic agents
may enhance the hypoglycemic effect of antidiabetic agents
may enhance the hypoglycemic effect of antidiabetic agents
may enhance the hypoglycemic effect of antidiabetic agents
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may increase the effect of insulins
may increase the effect of insulins
may increase the effect of insulins
may increase the effect of insulins
may increase the effect of insulins
may increase the vasoconstricting effect
may increase the vasoconstricting effect
may increase the vasoconstricting effect
may increase the vasoconstricting effect
may increase the vasoconstricting effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may have an increased hypoglycemic effect when combined with antidiabetic agents
may have an increased hypoglycemic effect when combined with antidiabetic agents
may have an increased hypoglycemic effect when combined with antidiabetic agents
may have an increased hypoglycemic effect when combined with antidiabetic agents
may have an increased hypoglycemic effect when combined with antidiabetic agents
may have an increased vasoconstricting effect when combined with ergot derivatives
may have an increased vasoconstricting effect when combined with ergot derivatives
may have an increased vasoconstricting effect when combined with ergot derivatives
it may diminish the metabolism when combined with azelastine
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
carvedilol: they may enhance the serum concentration of CYP2D6 Inhibitors
carvedilol: they may enhance the serum concentration of CYP2D6 Inhibitors
carvedilol: they may enhance the serum concentration of CYP2D6 Inhibitors
carvedilol: they may enhance the serum concentration of CYP2D6 Inhibitors
carvedilol: they may enhance the serum concentration of CYP2D6 Inhibitors
When carvedilol is used together with somatotropin, this leads to a rise in carvedilol metabolism
When ponesimod is used together with carvedilol, this leads to enhanced risk or seriousness of bradycardia
may have an increasingly adverse effect when combined with cannabis
may have an increasingly adverse effect when combined with cannabis
may have an increased orthostatic hypotensive effect when combined with alpha1-blockers
may have an increased orthostatic hypotensive effect when combined with alpha1-blockers
bunazosin (Not available in the United States)
may have an increased orthostatic hypotensive effect when combined with alpha1-blockers
may have an increased orthostatic hypotensive effect when combined with alpha1-blockers
may have an increased orthostatic hypotensive effect when combined with alpha1-blockers
When indisulam is used together with carvedilol, this leads to a reduction in carvedilol metabolism
may have an increased hypoglycemic effect when combined with insulins
may have an increased hypoglycemic effect when combined with insulins
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
carvedilol: it may increase the risk or severity of CNS depression
carvedilol: it may increase the risk or severity of CNS depression
carvedilol: it may increase the risk or severity of CNS depression
carvedilol: it may increase the risk or severity of CNS depression
carvedilol: it may increase the risk or severity of CNS depression
carvedilol: it may increase the risk or severity of CNS depression
carvedilol: it may increase the risk or severity of CNS depression
carvedilol: it may increase the risk or severity of CNS depression
carvedilol: it may increase the risk of adverse effects of oxtriphylline
carvedilol: it may increase the metabolism of CNS depressants
carvedilol: it may increase the metabolism of CNS depressants
carvedilol: it may increase the metabolism of CNS depressants
carvedilol: it may decrease the therapeutic efficacy of procaterol
When carvedilol is used together with adenine, this leads to a reduction in the carvedilol’s metabolism
carvedilol: it may decrease activities of antihypertensive drugs
carvedilol: it may decrease activities of antihypertensive drugs
carvedilol: it may decrease activities of antihypertensive drugs
carvedilol: it may decrease activities of antihypertensive drugs
carvedilol: it may decrease activities of antihypertensive drugs
there is a additive effect when beta-adrenergic blockers are combined with antiglaucoma agents
when both drugs are combined, there may be an increased risk or severity of adverse effects  
acetylcholinesterase Inhibitors May enhance the bradycardic effect of beta-Blockers
acetylcholinesterase Inhibitors May enhance the bradycardic effect of beta-Blockers
acetylcholinesterase Inhibitors May enhance the bradycardic effect of beta-Blockers
acetylcholinesterase Inhibitors May enhance the bradycardic effect of beta-Blockers
acetylcholinesterase Inhibitors May enhance the bradycardic effect of beta-Blockers
amiodarone may enhance the bradycardic effect of beta-blockers
may increase the av-blocking effect of beta-blockers
may increase the av-blocking effect of beta-blockers
may increase the av-blocking effect of beta-blockers
may increase the av-blocking effect of beta-blockers
may increase the av-blocking effect of beta-blockers
it enhances by affecting the hepatic enzyme CYP2D6 metabolism
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
it increases the effect of bradycardia of Beta-Blockers
Beta-Blockers increase the effect of hypoglycemia of insulins
Beta-Blockers increase the effect of hypoglycemia of insulins
Beta-Blockers increase the effect of hypoglycemia of insulins
Beta-Blockers increase the effect of hypoglycemia of insulins
Beta-Blockers increase the effect of hypoglycemia of insulins
may enhance the serum concentration of CYP2C9 inhibitors
may increase the toxic effect
may enhance the serum concentration of Beta-Blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may enhance the serum concentration when combined with mepivacaine
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may have an increased bradycardic effect when combined with beta-blockers
may have an increased bradycardic effect when combined with beta-blockers
may have an increased bradycardic effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may decrease the antihypertensive effect when combined with beta-blockers
may decrease the antihypertensive effect when combined with beta-blockers
may decrease the antihypertensive effect when combined with beta-blockers
may decrease the antihypertensive effect when combined with beta-blockers
may decrease the antihypertensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased bradycardic effect when combined with beta-blockers
may have an increased adverse effect when combined with cholinergic agonists
may have an increased adverse effect when combined with cholinergic agonists
may have an increased adverse effect when combined with cholinergic agonists
may have an increased adverse effect when combined with cholinergic agonists
may have an increased adverse effect when combined with cholinergic agonists
may have an increasingly adverse effect when combined with cannabis
may have an increasingly adverse effect when combined with cannabis
may decrease the therapeutic effect when combined with beta-blockers
the hyperkalemic activity of carvedilol may be increased
the bradycardic activity of carvedilol may be increased
the bradycardic activity of carvedilol may be increased
When carvedilol is used together with oliceridine, this leads to reduction in oliceridine’s metabolism
may decrease the bronchodilatory effect of beta-blockers
may decrease the bronchodilatory effect of beta-blockers
may decrease the bronchodilatory effect of beta-blockers
may enhance the serum concentration when combined with propranolol
may enhance the serum concentration when combined with propranolol
may enhance the serum concentration when combined with propranolol
may enhance the serum concentration when combined with propranolol
may enhance the serum concentration when combined with propranolol
May enhances the effects of the other by pharmacodynamic synergism
May enhances the effects of the other by pharmacodynamic synergism
May enhances the effects of the other by pharmacodynamic synergism
May enhances the effects of the other by pharmacodynamic synergism
May enhances the effects of the other by pharmacodynamic synergism
May enhances the effects of the other by pharmacodynamic synergism
May enhances the effects of the other by pharmacodynamic synergism
May enhances the effects of the other by pharmacodynamic synergism
May diminish the effects of carvedilol by pharmacodynamic antagonism
Frequency defined:Â Â
>10%Â
Weight gainÂ
HypotensionÂ
FatigueÂ
DiarrheaÂ
DizzinessÂ
Hyperglycemia Â
1-10%Â
NauseaÂ
CoughÂ
HeadacheÂ
AnginaÂ
HypercholesterolemiaÂ
VomitingÂ
DyspneaÂ
SyncopeÂ
RhinitisÂ
Bradycardia Â
<10%Â
InsomniaÂ
PalpitationsÂ
ImpotenceÂ
RalesÂ
DepressionÂ
HepatotoxicityÂ
ImpotenceÂ
Raynaud phenomenon Â
Post-marketing reportÂ
Urinary incontinenceÂ
Interstitial pneumonitisÂ
Aplastic anemiaÂ
UrticariaÂ
Stevens-johnson syndromeÂ
Be cautious with patients suffering from Chronic obstructive pulmonary disease, myocardial depression, hyperthyroidism, diabetes mellitus, pheochromocytoma, and myasthenia gravis.Â
Pregnancy consideration:Â Â
Insufficient data is available Â
US FDA pregnancy category: Not assigned Â
Lactation:Â Â Â
The drug is not excreted in the human breast milk Â
Pregnancy category:Â
Â
Patient information leafletÂ
Generic Name: CarvedilolÂ
Pronounced: [ KAR-ve-dil-ole] Â
Why do we use carvedilol?Â
Carvedilol treats hypertension (high blood pressure) and heart failure.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
